New Parkinson’s drug listed on PBS The adjunctive therapy for the treatment of Parkinson’s disease will help to maximise the effectiveness and longevity of existing medication.
Does vaccination reduce long COVID risk? Research suggests illness severity and vaccination status influence the chance of patients seeking medical care in the six months post-infection.
Major surgery risk for COPD patients People with COPD are significantly more likely to die in the year after a surgical procedure than otherwise similar patients, new research has found.
Next steps for new Alzheimer’s treatment Approved this month in the US, Alzheimer’s disease treatment lecanemab is yet to undergo the regulatory approval process in Australia.
Research finds trees in urban spaces promote heart health An analysis of 10 years of hospitalisation and death data shows urban green space, particularly trees, can reduce cardiovascular disease risk.
Antibiotics linked to inflammatory bowel disease Research shows a particularly high association between antibiotics and inflammatory bowel disease in mid-life and with repeated antibiotic courses.
PBS change allows GPs to prescribe evolocumab The medication, which can help prevent cardiovascular events, was previously restricted to certain non-GP specialists.
Ill health burden increases in Australia New statistics from the AIHW suggest that people spent more time unwell in 2022 than previous years – a trend driven by COVID-19.
Updated action plan for essential COPD management Dr Kerry Hancock gives an overview of the Lung Foundation’s updated COPD Action Plan to ensure best practice when self-managing exacerbations.
Rheumatic fever and heart disease Dhineli Perera chats to infectious diseases specialist Professor Anna Ralph about acute rheumatic fever and rheumatic heart disease. Who gets these conditions, how are they diagnosed, and how do we manage them?